CV and mad panic behaviour

[LP]

https://theconversation.com/why-the-oxfo...ger-150660

Yes, it's often the logistical issues that make or break a medicine, and something that doesn't need cryogenic distribution, as well as being suitable for tailored delivery, is a big game changer. The two features combine to deliver the cheapest and fastest global solution.

For example, you can give low risk populations a lower dose and still get partial protection, while high risk populations get the full booster and obtain very high levels of protection. Many of you are already familiar with vaccines that work this way, we've either been getting vaccines for travel or having our children immunised in that two stage/tier fashion for many decades.

What is even more exciting long term, is the idea a low cost effective vaccine like this might become available for the more common corona(cold) virus. While that won't really benefit healthy young people, there is a whole gamut of society that are at very high risk from a simple cold.

The Oxford team need special kudos, there two tier trial significantly compresses the process and I think that puts them in the lead, it's probably going to change how these things are done from now on, in the past this dose/efficacy part of the development would have been completed sequentially and added years to the process.